Zynerba Pharmaceuticals
Pharmaceuticals, 80 Lancaster Ave Ste 300, Devon, Pennsylvania, 19333, United States, 11-50 Employees
Phone Number: 14*********
Who is ZYNERBA PHARMACEUTICALS
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the developm...
Read More
-
Headquarters: 80 Lancaster Ave Ste 300, Devon, Pennsylvania, 19333, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Armando Anido
Email
Phone
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 561110 |
Show More
Does something look wrong? Fix it. | View contact records from ZYNERBA PHARMACEUTICALS
Zynerba Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Zynerba Pharmaceuticals
Answer: Zynerba Pharmaceuticals's headquarters are located at 80 Lancaster Ave Ste 300, Devon, Pennsylvania, 19333, United States
Answer: Zynerba Pharmaceuticals's phone number is 14*********
Answer: Zynerba Pharmaceuticals's official website is https://zynerba.com
Answer: Zynerba Pharmaceuticals's revenue is $1 Million to $5 Million
Answer: Zynerba Pharmaceuticals's SIC: 2834
Answer: Zynerba Pharmaceuticals's NAICS: 561110
Answer: Zynerba Pharmaceuticals has 11-50 employees
Answer: Zynerba Pharmaceuticals is in Pharmaceuticals
Answer: Zynerba Pharmaceuticals contact info: Phone number: 14********* Website: https://zynerba.com
Answer: Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile. Zynerbas lead patent-protected product candidate in clinical development is ZygelTM. Zygel is the first and only pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced cannabidiol and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder. Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions. Zynerba is developing a compelling wholly-owned clinical pipeline that may address significant unmet medical needs.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month